Base de dados : MEDLINE
Pesquisa : D02.355.291.411.408 [Categoria DeCS]
Referências encontradas : 61 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 61 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10696251
[Au] Autor:Duque JL; Loughlin KR
[Ad] Endereço:Department of Surgery, Children's Hospital, Boston, Massachusetts.
[Ti] Título:An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
[So] Source:Urol Clin North Am;27(1):125-35, x, 2000 Feb.
[Is] ISSN:0094-0143
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers. The vast majority of these cancers are transitional bladder tumors of various histologic grades (I to III). Superficial tumors include carcinoma in situ (CIS), tumors confined to the epithelium (Ta), and superficial tumors that invade the lamina propria (T1) but do not involve superficial muscle layers. The primary treatment for eradication of stage Ta and T1 bladder cancers is transurethral resection of the tumor. Many patients with superficial bladder tumors treated with endoscopic surgery alone have recurrence or tumor progression at some point in their follow-up, and, in these patients, the need for adjuvant treatment becomes a major concern.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intravesical
Antineoplásicos/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma in Situ/tratamento farmacológico
Ensaios Clínicos como Assunto
Terapia Combinada
Doxorrubicina/uso terapêutico
Epirubicina/uso terapêutico
Etoglucida/uso terapêutico
Seres Humanos
Imunoterapia
Mitomicina/uso terapêutico
Tiotepa/uso terapêutico
Neoplasias da Bexiga Urinária/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 3Z8479ZZ5X (Epirubicin); 4F9KUA0T4D (Ethoglucid); 50SG953SK6 (Mitomycin); 80168379AG (Doxorubicin); 905Z5W3GKH (Thiotepa)
[Em] Mês de entrada:0003
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:000304
[St] Status:MEDLINE


  2 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10476441
[Ti] Título:Triethylene glycol diglycidyl ether.
[So] Source:IARC Monogr Eval Carcinog Risks Hum;71 Pt 3:1539-41, 1999.
[Is] ISSN:1017-1606
[Cp] País de publicação:France
[La] Idioma:eng
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/toxicidade
Carcinógenos/toxicidade
Etoglucida/toxicidade
Rim/patologia
[Mh] Termos MeSH secundário: Animais
Carcinógenos/química
Carcinógenos/farmacocinética
Etoglucida/química
Etoglucida/farmacocinética
Seres Humanos
Rim/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Carcinogens); 4F9KUA0T4D (Ethoglucid)
[Em] Mês de entrada:9910
[Cu] Atualização por classe:161021
[Lr] Data última revisão:
161021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990907
[St] Status:MEDLINE


  3 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9259089
[Au] Autor:Badalament RA; Farah RN
[Ad] Endereço:Department of Urology, Henry Ford Hospital, Detroit, Michigan, USA.
[Ti] Título:Treatment of superficial bladder cancer with intravesical chemotherapy.
[So] Source:Semin Surg Oncol;13(5):335-41, 1997 Sep-Oct.
[Is] ISSN:8756-0437
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Proper care of patients with superficial bladder cancer requires the assessment of multiple factors, including an understanding of the natural history of this disease, accurate clinical staging, and the expected efficacy of each drug. The pharmacology of intravesical mytomycin C is discussed in detail, as many of this drug's pharmacological principles are applicable to all intravesical chemotherapeutic agents, including doxorubicin, thiotepa, bacillus Calmette-Guérin, epirubicin, and ethoglucid. The bladder wall, bladder cavity, chemical properties of intravesical chemotherapeutic agents, and tumor considerations are discussed. Suggestions based on pharmacological studies are presented to optimize the efficacy of intravesical chemotherapy.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intravesical
Antibióticos Antineoplásicos/administração & dosagem
Antibióticos Antineoplásicos/uso terapêutico
Antineoplásicos/administração & dosagem
Antineoplásicos Alquilantes/administração & dosagem
Antineoplásicos Alquilantes/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Vacina BCG/administração & dosagem
Vacina BCG/uso terapêutico
Doxorrubicina/administração & dosagem
Doxorrubicina/uso terapêutico
Epirubicina/administração & dosagem
Epirubicina/uso terapêutico
Etoglucida/administração & dosagem
Etoglucida/uso terapêutico
Seres Humanos
Mitomicina/administração & dosagem
Mitomicina/uso terapêutico
Estadiamento de Neoplasias
Tiotepa/administração & dosagem
Tiotepa/uso terapêutico
Resultado do Tratamento
Bexiga Urinária/efeitos dos fármacos
Neoplasias da Bexiga Urinária/patologia
Neoplasias da Bexiga Urinária/fisiopatologia
Neoplasias da Bexiga Urinária/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 0 (Antineoplastic Agents); 0 (Antineoplastic Agents, Alkylating); 0 (BCG Vaccine); 3Z8479ZZ5X (Epirubicin); 4F9KUA0T4D (Ethoglucid); 50SG953SK6 (Mitomycin); 80168379AG (Doxorubicin); 905Z5W3GKH (Thiotepa)
[Em] Mês de entrada:9710
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970901
[St] Status:MEDLINE


  4 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9224307
[Au] Autor:Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
[Ad] Endereço:University of Amsterdam, The Netherlands.
[Ti] Título:Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
[So] Source:J Urol;158(2):378-84, 1997 Aug.
[Is] ISSN:0022-5347
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: We compared the efficacy of transurethral resection alone or transurethral resection followed by bladder instillations of doxorubicin or ethoglucid for 1 year in patients with superficial bladder carcinoma, and followed them long term for the incidence of progression to muscle invasion. MATERIALS AND METHODS: A total of 443 patients with superficial transitional cell carcinoma of the bladder was randomized. After randomization of 206 patients the control arm was closed to patient entry based on the results of an interim analysis showing a significant difference in favor of those receiving adjuvant chemotherapy. RESULTS: Final analysis of treatment results for recurrence included 432 patients at a median followup of 3.4 years for time to first recurrence, 5 years for analysis of time to invasion (Category T2 disease or worse) and 10.7 years for duration of survival. Time to first recurrence was significantly prolonged by both drugs compared to transurethral resection alone (doxorubicin versus transurethral resection alone p < 0.001 and ethoglucid versus control p < 0.001). Recurrence rate per year was 0.30 for both adjuvant treatment arms and 0.68 for the resection only group. Progression to muscle invasion was rare (15.1% of cases) and not apparently different in the 3 treatment arms. Of the 423 patients death from any cause in 199 and from malignant disease in 59 was not correlated with treatment. However, there was a strong correlation between death from malignant disease, and T category and tumor grade. CONCLUSIONS: In regard to time to first recurrence and recurrence rate per year this study indicates that adjuvant chemotherapy with doxorubicin and ethoglucid using the indicated schedule is superior to transurethral resection alone. However, progression in stage or survival was not influenced by the treatment regimen.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/uso terapêutico
Carcinoma de Células de Transição/tratamento farmacológico
Carcinoma de Células de Transição/cirurgia
Doxorrubicina/uso terapêutico
Etoglucida/uso terapêutico
Neoplasias da Bexiga Urinária/tratamento farmacológico
Neoplasias da Bexiga Urinária/cirurgia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células de Transição/mortalidade
Carcinoma de Células de Transição/patologia
Carcinoma de Células de Transição/secundário
Quimioterapia Adjuvante
Progressão da Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Invasividade Neoplásica
Recidiva Local de Neoplasia/epidemiologia
Estadiamento de Neoplasias
Taxa de Sobrevida
Fatores de Tempo
Neoplasias da Bexiga Urinária/mortalidade
Neoplasias da Bexiga Urinária/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 4F9KUA0T4D (Ethoglucid); 80168379AG (Doxorubicin)
[Em] Mês de entrada:9708
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:970801
[St] Status:MEDLINE


  5 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8178408
[Au] Autor:Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
[Ad] Endereço:Urologische Abteilung, Krankenhauses St. Pölten.
[Ti] Título:[Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
[Ti] Título:Topische Immuntherapie (KLH) vs. Chemotherapie (Ethoglucid) in der Rezidivprophylaxe oberflächlicher Harnblasenkarzinome. Eine prospektiv randomisierte Studie..
[So] Source:Urologe A;33(2):138-43, 1994 Mar.
[Is] ISSN:0340-2592
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:A prospective randomized controlled study on the effect of KLH (keyhole limpet hemocyanin) versus etoglucid in the prevention of recurrences in primary and recurrent superficial transitional cell carcinoma of the bladder (stage pTa-pT1, grades 1-3 according to the recommendations of UICC and WHO) after complete transurethral resection of the tumor started in 198. Patients in group 1 (n = 76) were immunized with 1 mg KLH intracutaneously, after which they received bladder instillations of 30 mg (30 ml) KLH weekly for 6 weeks and then monthly for 1 year. Patients in group 2 (n = 85) received weekly bladder instillations of 0.565 g etoglucid (50 ml 1% solution) for 6 weeks and then monthly for 1 year. The percentage of recurrences, recurrence rate, disease-free interval and tumor progression rate were evaluated for both treatment groups. The end-point of the study was progression in stage or grade or more than two recurrences during the observation period. The shortest follow-up was 12 months, the mean follow-up, 27.5 months. No statistically significant differences were found between the two groups in percentage of recurrences (43.4% KLH-53.9% etoglucid), recurrence rate (4.4 KLH-3.9 etoglucid), mean disease-free interval (12.1 months KLH-13.6 months etoglucid) or progression rate (6.5% KLH-9.4% etoglucid).
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Carcinoma de Células de Transição/terapia
Etoglucida/administração & dosagem
Hemocianinas/administração & dosagem
Recidiva Local de Neoplasia/terapia
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/efeitos adversos
Administração Intravesical
Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células de Transição/patologia
Terapia Combinada
Etoglucida/efeitos adversos
Feminino
Seguimentos
Hemocianinas/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Recidiva Local de Neoplasia/patologia
Estadiamento de Neoplasias
Estudos Prospectivos
Neoplasias da Bexiga Urinária/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 4F9KUA0T4D (Ethoglucid); 9013-72-3 (Hemocyanins); FV4Y0JO2CX (keyhole-limpet hemocyanin)
[Em] Mês de entrada:9406
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:940301
[St] Status:MEDLINE


  6 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1636237
[Au] Autor:Thrasher JB; Crawford ED
[Ad] Endereço:Division of Urology, Duke University Medical Center, Durham, North Carolina.
[Ti] Título:Complications of intravesical chemotherapy.
[So] Source:Urol Clin North Am;19(3):529-39, 1992 Aug.
[Is] ISSN:0094-0143
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A variety of intravesical chemotherapeutic agents are now available for the treatment of superficial transitional-cell carcinoma of the bladder. The toxicities associated with these agents may make one more appealing than another in the face of similar efficacies. Intravesical instillations of thiotepa have resulted in incidences of leukopenia of 8% to 54%, of thrombocytopenia of 3% to 31%, and of irritative voiding symptoms of 12% to 69%. Close monitoring of blood counts prior to weekly instillations remains vital in preventing myelosuppressive complications. The complications associated with the intravesical use of mitomycin C are mainly chemical cystitis and contact dermatitis. Additionally, allergic reactions have been documented. Most of these complications respond to cessation of therapy with application of topical steroids as needed. Complications of reduced bladder capacity, bladder-wall calcifications, and myelosuppression are uncommon. Toxicities associated with the use of doxorubicin, epirubicin, and ethoglucid are almost exclusively local and usually described as mild to moderate dysuria, frequency, or urgency. Case reports of systemic reactions to doxorubicin are notable in that the patients responded well to diphenhydramine and, in one severe case, epinephrine. Other adverse effects such as reduced bladder capacity, fever, and nausea and vomiting are very uncommon. New agents, such as mitoxantrone, are undergoing phase I and phase II studies. The ideal agent, which would be highly effective and minimally toxic, remains to be developed.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Carcinoma de Células de Transição/tratamento farmacológico
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intravesical
Antineoplásicos/administração & dosagem
Doxorrubicina/efeitos adversos
Epirubicina/efeitos adversos
Etoglucida/efeitos adversos
Seres Humanos
Mitomicina/efeitos adversos
Mitoxantrona/efeitos adversos
Tiotepa/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 3Z8479ZZ5X (Epirubicin); 4F9KUA0T4D (Ethoglucid); 50SG953SK6 (Mitomycin); 80168379AG (Doxorubicin); 905Z5W3GKH (Thiotepa); BZ114NVM5P (Mitoxantrone)
[Em] Mês de entrada:9208
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:920801
[St] Status:MEDLINE


  7 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1611114
[Au] Autor:Hoeltl W; Hasun R; Albrecht W
[Ad] Endereço:Department of Urology, Krankenanstalt Rudolfstiftung, Vienna, Austria.
[Ti] Título:Prospective, randomized trial to evaluate high-versus low-dose interferon-alpha 2b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder.
[So] Source:Anticancer Drugs;3 Suppl 1:29-32, 1992 May.
[Is] ISSN:0959-4973
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Forty-four patients with superficial bladder cancer were randomized to receive 10 MU (14 patients) or 100 MU (14 patients) of interferon (IFN)-alpha 2b or 1.3 g ethoglucid (16 patients) instilled into the bladder once weekly for 10 weeks and then monthly for 1 year. Efficacy (evaluated in 34 patients who completed the course of treatment), based on recurrence rate and time to first recurrence, was similar in the three groups. No systemic toxicity of treatment was seen. Severe chemocystitis occurred in some patients who received ethoglucid (three had to discontinue treatment), while no local toxicity was seen with IFN-alpha 2b treatment.
[Mh] Termos MeSH primário: Carcinoma de Células de Transição/prevenção & controle
Etoglucida/administração & dosagem
Interferon-alfa/administração & dosagem
Recidiva Local de Neoplasia/prevenção & controle
Neoplasias da Bexiga Urinária/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Avaliação de Medicamentos
Etoglucida/efeitos adversos
Feminino
Seres Humanos
Masculino
Meia-Idade
Proteínas Recombinantes
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Interferon-alpha); 0 (Recombinant Proteins); 43K1W2T1M6 (interferon alfa-2b); 4F9KUA0T4D (Ethoglucid)
[Em] Mês de entrada:9207
[Cu] Atualização por classe:161123
[Lr] Data última revisão:
161123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920501
[St] Status:MEDLINE


  8 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1394828
[Au] Autor:van der Meijden AP; Kurth KH; Oosterlinck W; Debruyne FM
[Ad] Endereço:Department of Urology, University Hospital Nijmegen, The Netherlands.
[Ti] Título:Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.
[So] Source:Cancer Chemother Pharmacol;30 Suppl:S95-8, 1992.
[Is] ISSN:0344-5704
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The anthracycline derivatives Adriamycin and 4-epirubicin are used to prevent recurrent tumors after transurethral resection of superficial bladder tumors. Both drugs are instilled intravesically. The present report describes the results of two multicenter, prospective, randomized phase III studies carried out by the EORTC GU Group. In protocol 30,790, after a mean follow-up period of 26.6 months, the recurrence rate for 165 patients treated with Adriamycin was 0.29 and the tumor rate was 0.74. For 156 patients treated with Epodyl, the recurrence rate was 0.29 and the tumor rate was 0.57. This difference was not statistically significant. For 70 patients who received transurethral resection alone, the recurrence rate was 0.65 and the tumor rate, 2.04. In protocol 30,763, patients with good prognostic factors were treated with one single instillation of 4-epirubicin versus sterile water. After a mean follow-up period of 16 months, in 190 patients treated with 4-epirubicin the recurrence rate was 0.20 and the tumor rate was 0.35; in 196 patients treated with sterile water, the recurrence rate was 0.37 and the tumor rate was 0.65 (P = 0.0001). Adriamycin and 4-epirubicin were efficacious, and severe side effects were not encountered. The superiority of Adriamycin over Epodyl could not be proven.
[Mh] Termos MeSH primário: Doxorrubicina/uso terapêutico
Epirubicina/uso terapêutico
Etoglucida/uso terapêutico
Recidiva Local de Neoplasia/prevenção & controle
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intravesical
Quimioterapia Adjuvante
Seres Humanos
Recidiva Local de Neoplasia/tratamento farmacológico
Estudos Prospectivos
Neoplasias da Bexiga Urinária/cirurgia
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
3Z8479ZZ5X (Epirubicin); 4F9KUA0T4D (Ethoglucid); 80168379AG (Doxorubicin)
[Em] Mês de entrada:9211
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920101
[St] Status:MEDLINE


  9 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1993279
[Au] Autor:Flamm J; Bucher A
[Ad] Endereço:Department of Urology, Wilhelminen Hospital, Vienna, Austria.
[Ti] Título:Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.
[So] Source:Br J Urol;67(1):70-3, 1991 Jan.
[Is] ISSN:0007-1331
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole-limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder. Patients treated with ethoglucid (n = 39) received 0.565 g (1% solution) ethoglucid weekly for 6 weeks and then monthly for 1 year. Patients treated with KLH (n = 38) were immunised subcutaneously with 1 mg KLH; bladder instillations of 30 mg were then given weekly for 6 weeks and thereafter monthly for 1 year. The recurrence rates, disease-free intervals and tumour progression rates were evaluated. The end-point of the study was either progression in stage or grade or more than 1 recurrence during the observation period. The minimum length of follow-up was 1 year. The recurrence rates, mean disease-free intervals and progression rates in the 2 groups showed no statistically significant differences.
[Mh] Termos MeSH primário: Carcinoma de Células de Transição/terapia
Etoglucida/uso terapêutico
Hemocianinas/uso terapêutico
Imunoterapia
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Administração Intravesical
Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células de Transição/cirurgia
Terapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Recidiva Local de Neoplasia/prevenção & controle
Estudos Prospectivos
Fatores de Risco
Neoplasias da Bexiga Urinária/cirurgia
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
4F9KUA0T4D (Ethoglucid); 9013-72-3 (Hemocyanins); FV4Y0JO2CX (keyhole-limpet hemocyanin)
[Em] Mês de entrada:9103
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:910101
[St] Status:MEDLINE


  10 / 61 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:1747725
[Au] Autor:Hoeltl W; Hasun R; Albrecht W; Marberger M
[Ad] Endereço:Department of Urology, Rudolfstiftung Hospital, Vienna, Austria.
[Ti] Título:How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
[So] Source:Br J Urol;68(5):495-8, 1991 Nov.
[Is] ISSN:0007-1331
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A total of 44 patients with low and intermediate grade superficial urothelial bladder cancer Ta and T1 were randomised into a controlled, long-term, phase III trial on topical instillation therapy with high dose alpha-2b interferon (100 x 10(6) IU versus low dose alpha-2b interferon (10 x 10(6) IU) versus ethoglucid. Thirteen patients in the low dose group, 11 in the high dose group and 10 in the ethoglucid group completing the trial were evaluable (median follow-up 36.5 months) and were followed up for 3 years. They were treated weekly for 10 weeks and then monthly for a total of 1 year. The aim of the trial was to establish the prophylactic efficacy and the toxic side effects, if any, of alpha-2b interferon in the topical treatment of superficial bladder cancer. Recurrence rate and disease-free survival were chosen as study end-points. The recurrence rate was 4.4 in the low dose interferon group, 2.76 in the high dose interferon group and 3.08 in the ethoglucid group. In the low dose interferon group the time to the first recurrence was 22.23 months versus 22.36 in the high dose group and 21.76 months in the ethoglucid group. No differences of statistical significance were noted between the 3 groups. Progression occurred in 5 patients on interferon but was not seen in those on ethoglucid. Neither systemic nor local side effects were seen in the interferon groups, but 3 patients had to be taken off ethoglucid because of severe chemocystitis. In superficial bladder cancer, topical instillation therapy with interferon is as effective as conventional chemotherapy and has no side effects.
[Mh] Termos MeSH primário: Carcinoma de Células de Transição/prevenção & controle
Interferon-alfa/administração & dosagem
Recidiva Local de Neoplasia/prevenção & controle
Neoplasias da Bexiga Urinária/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intravesical
Idoso
Idoso de 80 Anos ou mais
Etoglucida/administração & dosagem
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Proteínas Recombinantes
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Interferon-alpha); 0 (Recombinant Proteins); 43K1W2T1M6 (interferon alfa-2b); 4F9KUA0T4D (Ethoglucid)
[Em] Mês de entrada:9201
[Cu] Atualização por classe:161123
[Lr] Data última revisão:
161123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:911101
[St] Status:MEDLINE



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde